- Home
- XPEV vs MRNA Comparison
XPEV vs MRNA Comparison
Compare XPEV & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEV | MRNA |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | China | United States |
| Employees | 16631 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 19.7B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | XPEV | MRNA |
|---|---|---|
| Price | $17.36 | $50.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 12 |
| Target Price | $23.08 | ★ $34.27 |
| AVG Volume (30 Days) | ★ 5.6M | 5.3M |
| Earning Date | 05-20-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $26.17 | $8.74 |
| Revenue Next Year | $27.44 | $16.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $15.38 | $22.28 |
| 52 Week High | $28.20 | $59.55 |
Technical Indicators
Market Signals| Indicator | XPEV | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 50.91 |
| Support Level | $15.93 | $47.61 |
| Resistance Level | $18.88 | $54.94 |
| Average True Range (ATR) | 0.61 | 2.53 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 39.82 | 50.66 |
Price Performance
Historical ComparisonAbout XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.